EMA to review insulin glargine analog from Lilly, Boehringer

Eli Lilly and Co. (NYSE:LLY) and partner Boehringer Ingelheim GmbH (Ingelheim, Germany) said EMA accepted for review an MAA for LY2963016 to treat Type I and II diabetes. Lilly said the basal insulin glargine analog has the same amino acid sequence as Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY) and therefore was filed through EMA's biosimilar pathway. An NDA submission to FDA is slated for this year, though Lilly declined to disclose details. ...